Key result
Combined estrogen/progestin oral contraceptive use in healthy populations is associated with minimal adverse cardiovascular effects, with rates of angina and MI similar to or lower than non-users.
Why the study?
Do combined estrogen/progestin oral contraceptives increase the risk of cardiovascular disease in women?
Population
Current and past users of combined estrogen/progestin oral contraceptives, particularly healthy users…
Comparison
Combined estrogen/progestin oral contraceptives vs Non-users
Design
Review
Authors
Loading...
May reassure on CV safety for healthy users; leaves open need for RCTs in higher-risk groups.
Do combined estrogen/progestin oral contraceptives increase the risk of cardiovascular disease in women?
Current evidence suggests that in healthy users, modern oral contraceptives provide significant benefits with minimal adverse cardiovascular effects, though venous thromboembolism risk persists.
Victory et al. (2005) conducted a review in Cardiovascular disease. Combined estrogen/progestin oral contraceptives vs. Non-users was evaluated on Cardiovascular disease (venous thromboembolism, myocardial infarction, stroke). Combined estrogen/progestin oral contraceptive use in healthy populations is associated with minimal adverse cardiovascular effects, with rates of angina and MI similar to or lower than non-users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: